We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has c... Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. Show more
Across 50 treated patients, palazestrant (OP-1250) in combination with ribociclib was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug...
Completed enrollment in 60-patient Phase 1b/2 clinical studies of palazestrant in combination with each of ribociclib and palbociclibNew clinical data from palazestrant-ribociclib combination...
SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.46 | -13.4935304991 | 10.82 | 11.2 | 9.24 | 847849 | 9.69569266 | CS |
4 | -0.64 | -6.4 | 10 | 11.4 | 9.1601 | 763652 | 10.02541476 | CS |
12 | -4.22 | -31.0751104566 | 13.58 | 15.32 | 9.1601 | 850963 | 11.18033375 | CS |
26 | -4.9 | -34.3618513324 | 14.26 | 16.775 | 9.1601 | 878312 | 12.2132968 | CS |
52 | 2.47 | 35.8490566038 | 6.89 | 17.7911 | 5.02 | 631307 | 11.84727287 | CS |
156 | -15.69 | -62.6347305389 | 25.05 | 32.77 | 2 | 449875 | 11.27799701 | CS |
260 | -37.64 | -80.085106383 | 47 | 60.27 | 2 | 407971 | 12.90901057 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions